SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
ImmunityFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

Thymalin

Also known as thymic polypeptide, calf thymus extract

Thymalin is a polypeptide complex extracted from calf thymus, developed in the Soviet Union by the Khavinson group in the 1970s-80s. It is not a single defined molecule but a heterogeneous mixture of short peptides marketed as an immune bioregulator. Thymalin is registered as a medicinal product in Russia and several former-Soviet states for immune reconstitution after infection, radiation, surgery, and in elderly populations. It is not approved in the US, EU, or UK, and most published clinical literature is Russian-language.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Thymalin is a heterogeneous polypeptide complex extracted from calf thymus, containing short peptides including dipeptides EW (Thymogen-like) and KE and the tripeptide EDP. Proposed mechanisms include restoration of T-helper/T-suppressor balance, enhancement of NK cell activity, normalization of cytokine profiles, stimulation of bone-marrow lymphopoiesis, and modest anti-inflammatory effects via cytokine modulation.

Thymalin is a heterogeneous polypeptide complex extracted from calf thymus, containing short peptides including dipeptides EW (Thymogen-like) and KE and the tripeptide EDP. Proposed mechanisms include restoration of T-helper/T-suppressor balance, enhancement of NK cell activity, normalization of cytokine profiles, stimulation of bone-marrow lymphopoiesis, and modest anti-inflammatory effects via cytokine modulation. Reported in vitro work suggests modulation of hematopoietic stem-cell differentiation (PMID 33575961). Because the product is a complex mixture of short peptides rather than a single defined molecule, no individual receptor interaction defines its activity (Khavinson, PMID 6335878).

Pharmacokinetic properties

Half-life

unknown - heterogeneous peptide mixture; individual components are short-lived in plasma

Routes

intramuscular · subcutaneous

Bioavailability

Lyophilized powder reconstituted in saline or 0.5% procaine. No formal PK characterization.

Amino-acid sequence

Polypeptide complex derived from calf thymus (a mixture of short peptides including dipeptides EW and KE, and tripeptide EDP)

Use & research dosing

Immune BalanceImmune ModulationImmune SupportRecovery

Russian clinical dosing schedules are 10-30 mg intramuscular daily for 5-10 day courses, repeated 2-3 times per year. Lyophilized powder is reconstituted in saline or 0.5% procaine before injection. Self-experimentation protocols commonly report 5-10 mg SC or IM daily for 10-day cycles, sometimes followed by lower-frequency maintenance dosing of 1-2 injections per week. No FDA-approved dose exists. Research framing only outside Russia.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Current state: Thymalin has a long Russian clinical history but minimal Western regulatory or peer-reviewed footprint. Independent replication of efficacy claims outside the Khavinson institute is essentially absent. Because Thymalin is a bovine extract rather than a defined peptide, vendor product identity is difficult to verify. Mechanistic claims should be treated as hypothesis-generating rather than established pharmacology.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Bovine-derived biologic — theoretical risk of allergic or hypersensitivity reaction
  • Heterogeneous peptide mixture — batch-to-batch composition variability
  • Pregnancy and breastfeeding — limited data
  • Active autoimmune disease — caution with immune-modulating agents
  • Hematologic malignancy or marrow disorders — theoretical concern with hematopoietic stimulation
  • Pediatric use only under specialist supervision in Russian practice
  • Limited Western peer-reviewed safety data — most evidence is Russian-language
  • Vendor purity, endotoxin levels, and bovine-source traceability variable

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/6335878/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/33575961/

Facts verified

2026-05-25

Confidence

low

What this means

  • evidence base is primarily Russian-language / Khavinson institute
  • heterogeneous bovine extract — not a defined molecule
  • no Western regulatory approval or independent replication
  • vendor product identity hard to verify

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.